Viewing data from:

SEVELAMER CARBONATE

ANDA

SEVELAMER CARBONATE | A215998 | SHANDONG XINHUA PHARMACEUTICAL CO LTD

1 strength0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 1 NDC

Highest NADAC/Unit

$0.2186

per ea

Lowest NADAC/Unit

$0.2186

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
11788011607SEVELAMER CARBONATE 800 MG TAB	$0.2186	EA	Generic	—	2026-08-26

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain14 active DMFs6 inactive

12 active API suppliers hold Drug Master Files for this ingredient.

LUPIN MANUFACTURING SOLUTIONS LTDSEVELAMER CARBONATE

DMF 222932008

SOLARA ACTIVE PHARMA SCIENCES LTDSEVELAMER CARBONATE

DMF 229402009

FORMOSA LABORATORIES INCSEVELAMER CARBONATE

DMF 230392009

EMCURE PHARMACEUTICALS LTDSEVELAMER CARBONATE (FOR POWDER FORMULATION)

DMF 234592010

SUN PHARMACEUTICAL INDUSTRIES LTDSEVELAMER CARBONATE

DMF 245872011

EMCURE PHARMACEUTICALS LTDSEVELAMER CARBONATE (PROCESS II)

DMF 250392011

MATRIX PHARMACORP PRIVATE LTDSEVELAMER CARBONATE

DMF 256392011

NAVINTA LLCSEVELAMER CARBONATE

DMF 274052014

APITORIA PHARMA PRIVATE LTDSEVELAMER CARBONATE

DMF 279262014

FORMOSA LABORATORIES INCSEVELAMER CARBONATE

DMF 300022015

HETERO DRUGS LTDSEVELAMER CARBONATE

DMF 305692016

SHANDONG XINHUA PHARMACEUTICAL CO LTDSEVELAMER CARBONATE

DMF 353262020

WATERSTONE PHARMACEUTICALS (HUBEI) CO LTDSEVELAMER CARBONATE

DMF 369292022

AMI LIFESCIENCES PRIVATE LTDSEVELAMER CARBONATE

DMF 379812023

CHEMO IBERICA SA MADRIDInactiveSEVELAMER CARBONATE

DMF 222622008

EMCURE PHARMACEUTICALS LTDInactiveSEVELAMER CARBONATE (E SUB)

DMF 231642009

CHEMO IBERICA SAInactiveSEVELAMER CARBONATE

DMF 233882009

USV LTDInactiveSEVELAMER CARBONATE

DMF 253572011

HETERO DRUGS LTDInactiveSEVELAMER CARBONATE

DMF 262062012

CTX LIFE SCIENCES PVT LTDInactiveSEVELAMER CARBONATE

DMF 282992014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 800MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Oct 24, 2024

No patent or exclusivity listings for this strength.